Iontophoresis of vidarabine monophosphate for herpes orolabialis

Louis P. Gangarosa; James M. Hill; Barry L. Thompson; Carol Leggett; J. Peter Kissing

doi:10.1093/infdis/154.6.930

Iontophoresis of vidarabine monophosphate for herpes orolabialis

Louis P. Gangarosa
, James M. Hill
, Barry L. Thompson
, Carol Leggett
, J. Peter Kissing

Division of Infectious Diseases

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.

Original language	English (US)
Pages (from-to)	930-934
Number of pages	5
Journal	Journal of Infectious Diseases
Volume	154
Issue number	6
DOIs	https://doi.org/10.1093/infdis/154.6.930
State	Published - 1986

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1093/infdis/154.6.930

Cite this

@article{5c72f3c328324c5bbd891d035fe7c96c,

title = "Iontophoresis of vidarabine monophosphate for herpes orolabialis",

abstract = "The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.",

author = "Gangarosa, \{Louis P.\} and Hill, \{James M.\} and Thompson, \{Barry L.\} and Carol Leggett and \{Peter Kissing\}, J.",

note = "Funding Information: Receivedfor publication 27 February 1986,and in revised form 6 June 1986. Informed consent was obtained from all subjects as required by the Medical College of Georgia Human Assurance Committee, which follows the guidelines for human clinical experimentation of the U.S. Department of Health and Human Services. This study was supported in part by grants NIDR DE 06136 and EY 06311 from the National Institutes of Health. We thank Dr. P. K. Morse and Rollie J. Harp for statistical help; Rhesa Dykes and Dwayne McGahee for assistance in titration of virus; JoBeth Dudley for assistance in training the technicians to achieve consistency in results; the technicians for maintaining the secrecy of the drug codes; Barbara Smith and Jeannie Burris, nurse-researchers, for assistance in management of subject care and analysis of results; Mike Jones and Earl Berman for assistance in manuscript preparation; and Drs. S. L. Spruance (Salt Lake City) and H. E. Kaufman (New Orleans) for reading the manuscript and for suggestions. Please address requests for reprints to Dr. Louis P. Gangarosa, Sr., Department of Oral Biology (Pharmacology), School of Dentistry, Medical College of Georgia, Augusta, Georgia 30912-3366.",

year = "1986",

doi = "10.1093/infdis/154.6.930",

language = "English (US)",

volume = "154",

pages = "930--934",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "6",

}

TY - JOUR

T1 - Iontophoresis of vidarabine monophosphate for herpes orolabialis

AU - Gangarosa, Louis P.

AU - Hill, James M.

AU - Thompson, Barry L.

AU - Leggett, Carol

AU - Peter Kissing, J.

N1 - Funding Information: Receivedfor publication 27 February 1986,and in revised form 6 June 1986. Informed consent was obtained from all subjects as required by the Medical College of Georgia Human Assurance Committee, which follows the guidelines for human clinical experimentation of the U.S. Department of Health and Human Services. This study was supported in part by grants NIDR DE 06136 and EY 06311 from the National Institutes of Health. We thank Dr. P. K. Morse and Rollie J. Harp for statistical help; Rhesa Dykes and Dwayne McGahee for assistance in titration of virus; JoBeth Dudley for assistance in training the technicians to achieve consistency in results; the technicians for maintaining the secrecy of the drug codes; Barbara Smith and Jeannie Burris, nurse-researchers, for assistance in management of subject care and analysis of results; Mike Jones and Earl Berman for assistance in manuscript preparation; and Drs. S. L. Spruance (Salt Lake City) and H. E. Kaufman (New Orleans) for reading the manuscript and for suggestions. Please address requests for reprints to Dr. Louis P. Gangarosa, Sr., Department of Oral Biology (Pharmacology), School of Dentistry, Medical College of Georgia, Augusta, Georgia 30912-3366.

PY - 1986

Y1 - 1986

N2 - The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.

AB - The cutaneous application of antiviral agents was studied by iontophoresis, a process that increases penetration of most drugs 20- to 60-fold. Twenty-seven subjects with vesicular orolabial herpes were treated one time in a double-blind, placebo-controlled clinical study: nine received vidarabine monophosphate (ara-AMP), nine received acyclovir (ACV), and nine received NaCl. Ara-AMP-treated lesions yielded lower titers of virus after 24 hr compared with lesions treated with NaCl or ACV (P < .05) and time to dry crust (P < .05) compared with the other two agents. There was a trend toward decreased healing time after ara-AMP treatment.

UR - https://www.scopus.com/pages/publications/0023020053

UR - https://www.scopus.com/pages/publications/0023020053#tab=citedBy

U2 - 10.1093/infdis/154.6.930

DO - 10.1093/infdis/154.6.930

M3 - Article

C2 - 2431074

AN - SCOPUS:0023020053

SN - 0022-1899

VL - 154

SP - 930

EP - 934

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 6

ER -

Iontophoresis of vidarabine monophosphate for herpes orolabialis

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this